Skip to main content
ENANTA PHARMACEUTICALS INC logo

ENANTA PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · ENTA ISIN · US29251M1062 LEI · 529900SSN4DODDQSN594 US Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2025-10-09 Major Shareholding Noti…
Country US United States of America
Listing US ENTA

About ENANTA PHARMACEUTICALS INC

https://www.enanta.com/

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule drugs, with a focus on virology and immunology. The company utilizes a robust, chemistry-driven approach to create novel oral therapeutics for diseases with high unmet medical needs. Enanta has a significant track record of success, having developed protease inhibitors that are key components of treatment regimens for chronic hepatitis C virus (HCV) infection, which have cured over one million patients. Its current clinical pipeline is primarily focused on developing treatments for respiratory syncytial virus (RSV) and advancing its immunology programs for inflammatory diseases.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-09 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 1, 2025, reporting a public offering of common stock by Enanta Pharmaceuticals, Inc. It details the underwriting agreement, number of shares offered, price, net proceeds, and related legal opinions. There are no financial statements or quarterly/yearly financial results presented. The content focuses on a capital raising event through a public offering. This matches the definition of a Capital/Financing Update (CAP). The document length is about 6910 characters, which is sufficient to contain substantive information about the offering, not just an announcement or a brief notice. Therefore, the correct classification is CAP with high confidence.
2025-10-01 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and accompanying prospectus for a public offering of common stock by Enanta Pharmaceuticals, Inc. It includes information about the offering size, underwriting details, risk factors, use of proceeds, dividend policy, and legal matters. The document references a shelf registration statement on Form S-3 and is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing related to securities offerings. This type of document is specifically related to capital raising activities and financing updates rather than financial results, management changes, or other report types. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief notice, confirming it is not a mere report publication announcement or regulatory filing. Confidence in this classification is high due to the clear nature of the document as a prospectus supplement for a stock offering.
2025-10-01 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to an offering of common stock by Enanta Pharmaceuticals, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company overview. The document references SEC registration numbers and is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing related to securities offerings. This type of document is a capital markets filing that provides updates on fundraising activities and terms of the offering, rather than a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback, but a substantive financing document.
2025-09-30 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 29, 2025. It announces positive topline data from a Phase 2b study and includes a presentation as an exhibit. The text explicitly states that the presentation is furnished as Exhibit 99.1 and is intended to be "furnished" and not "filed" for certain regulatory purposes. The document is short (3932 characters) and primarily serves as an announcement of the data release and presentation, not a full financial or operational report. There are no detailed financial statements or substantive financial data included. The nature of the content and the inclusion of a presentation slide deck aligns with an Investor Presentation rather than an Annual Report, Earnings Release, or other detailed financial filings. Therefore, the most appropriate classification is Investor Presentation (IP).
2025-09-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the announcement of positive topline data from a Phase 2b clinical study of a drug candidate, zelicapavir, including study design, results, and safety profile. There are no comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, audit report, or management change announcement. It is primarily a regulatory filing to disclose material clinical trial results and related press release. The document length (10,789 characters) is substantial but the content is an event announcement rather than a full financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2025-09-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.